An EpiPen alternative is about to return to your local pharmacy

(By Ed Silverman for STAT)

The controversial EpiPen device is about to get still more competition.

A company that now has the rights to a rival product1 plans to start marketing its allergic-reaction device in the first half of 2017. However, Kaleo Pharma declined to disclose the pricing for its Auvi-Q, which had previously been sold by Sanofi before being withdrawn2 late last year over reports that the device delivered inaccurate doses. Continue reading article here……

stat-logo

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.